Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

NCT04130516 is registered in ClinicalTrials.gov with Linnaeus Therapeutics, Inc. as lead sponsor.

NCT NCT04130516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04130516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab
Lead sponsor
Linnaeus Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 21, 2019
Completion date
August 15, 2026
Enrollment
200 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult